App-Quantinova.ai

Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: results from the ALLEGRO Phase 2b/3, randomized, double-blind, placebo-controlled trial

Brett King - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Frovatriptan succinate

Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Natasha Mesinkovska - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Frovatriptan succinate

IMPACT OF DAY-TO-DAY SLEEP DISRUPTION ON THE BURDEN OF DISEASE IN MODERATE-SEVERE ADULT ATOPIC DERMATITIS PATIENTS

Evangeline Pierce - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Atopic Dermatitis

N/A

Early Response with Ixekizumab Predicts Long-Term Outcomes up to 5 Years in Psoriasis by Unsupervised and Supervised Machine Learning Analyses

Alexander Egeberg - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

LY2439821

Porokeratotic eccrine ostial and dermal duct nevus caused by a second-hit postzygotic GJB2 mutation

Hsing-San Yang - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Mortality in patients with pemphigus: a retrospective US claims database study

Jonathan Silverberg - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pemphigus

N/A

Telehealth Use at a Specialty Hidradenitis Suppurativa Clinic during the COVID-19 Pandemic

Diana S. Kim - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hidradenitis Suppurativa

N/A

Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes and Depression Screening: Findings From the Multinational UPLIFT Survey

Richard G. Langley - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

Time to Improvement in Daily Signs and Symptoms Associated With Atopic Dermatitis (AD) in Patients With Moderate-to-Severe AD in Pooled Monotherapy Studies of Abrocitinib

Melinda J Gooderham - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Minimum resection margins for fibrohistiocytic tumors: a systematic review to inform a probability model

Rachel E. Christensen - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Sarcoma

N/A

Dupilumab Provides Long-Term Improvement in Sleep Loss in Children, Adolescents, and Adults With Atopic Dermatitis

Amy S. Paller - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Improvement in Disease Severity and Quality of Life in Patients With Atopic Dermatitis (AD) Treated With Dupilumab for up to 18 Months: Real-World Evidence From the PROSE Registry

Jerry Bagel - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data

Craig Leonardi - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

bimekizumab

Real-World Analysis of Skin Infections and Antimicrobial Use Among Patients With Atopic Dermatitis Before and After Initiation of Dupilumab Treatment

Peck Ong - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Baseline Patient Demographics and Comorbidities in Patients With Atopic Dermatitis From the GLOBOSTAD Registry

Piergiacomo Calzavara-Pinton - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Treatment Patterns and Prior Medication Usage Before Dupilumab Treatment Initiation in Patients With AD: Real-World Data From GLOBOSTAD

Silvia M. Ferrucci - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Dupilumab

Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension (OLE) Trial up to 4 years

Andreas Wollenberg - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

bimekizumab

Pustular psoriasis of pregnancy: a unique presentation

Olivia Negris - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Psoriasis 14, pustular

N/A

Deucravacitinib Exposure-Response Analyses in Patients With Moderate to Severe Psoriasis

Jun Shen - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

N/A

Filters

45280 Abstracts